Cytokinetics, Incorporated Cash Flow Statement Analysis

Operating, investing, and financing activities in billions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Cytokinetics, Incorporated (CYTK) - Annual data in billions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-0.59-0.53-0.39-0.22-0.13-0.12-0.11
Depreciation & Amortization0.010.000.000.010.000.000.00
Stock Based Compensation0.100.070.050.030.020.000.00
Change in Working Capital0.040.00-0.03-0.040.090.00-0.02
Change in Accounts Receivable-0.020.000.06-0.050.000.000.00
Change in Accounts Payable0.000.000.000.000.000.000.00
Change in Other Working Capital0.000.020.060.050.000.000.00
Other Operating Activities0.050.110.090.100.050.030.02
Net Cash from Operating Activities-0.40-0.41-0.30-0.140.01-0.09-0.10
Investing Activities
Capital Expenditures0.000.000.010.050.010.000.00
Purchases of Investments-0.55-0.64-0.86-0.10-0.190.000.00
Sales/Maturities of Investments0.74-0.64-0.25-0.10-0.19-0.070.01
Net Cash from Investing Activities-0.550.24-0.26-0.15-0.20-0.070.01
Financing Activities
Debt Repayment-0.010.00-0.050.000.000.000.00
Common Stock Issued0.760.160.020.020.040.040.00
Common Stock Repurchased-0.02-0.01-0.010.000.000.000.00
Other Financing Activities0.200.040.030.290.190.120.00
Net Cash from Financing Activities0.930.220.520.320.230.160.01
Summary
Effect of Forex Changes on Cash0.000.000.000.000.000.000.00
Net Change in Cash-0.020.05-0.050.030.05-0.01-0.08
Cash at Beginning of Period0.110.070.110.080.040.040.13
Cash at End of Period0.10-1.050.070.110.080.040.04
Free Cash Flow-0.40-0.41-0.31-0.190.00-0.09-0.10
Supplemental Disclosures
Interest Paid0.030.010.020.010.010.000.00
Income Taxes Paid0.000.000.000.000.000.000.00